ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
26 announcements
Choksi Laboratories Ltd has scheduled an EGM for October 17, 2026, to seek shareholder approval for issuing 3.50 lakh convertible warrants at ₹177 per warrant.
Choksi Laboratories board approved a preferential issue of 3.5 lakh warrants to promoters at Rs 177 per warrant, totaling Rs 6.195 Crore.
Choksi Laboratories filed proceedings of its 33rd AGM held on 18 September 2026. Directors Sunil Choksi and Himika Choksi were re-appointed as Whole-Time Directors.
Choksi Laboratories announced a Board meeting on September 19, 2026, to discuss a proposal for raising funds through equity or convertible securities.
Choksi Laboratories Limited has dispatched letters to shareholders with unregistered email addresses. The communication provides access details for the FY 2025-26 Annual Report and AGM notice.
Choksi Laboratories has submitted its 33rd Annual Report for the financial year 2025-26. The report and the notice of the upcoming AGM are now available.
Choksi Laboratories Limited has issued the notice for its 33rd Annual General Meeting, scheduled to be held on September 18, 2026, through video conferencing.
Choksi Laboratories reported that the USFDA inspected its central laboratory in Indore. The inspection concluded with four observations, which the company is currently addressing.
Choksi Laboratories has reappointed M/s Tanmay V. Rajurkar & Co. as the company's internal auditor for the financial year 2026-27.
Choksi Laboratories Ltd has re-appointed Ms. Himika Choksi as Whole Time Director for a five-year term effective from April 1, 2027, subject to shareholder approval.
Choksi Laboratories Ltd reported revenue from operations of ₹12.1 Cr (+8.0% YoY) and net profit of ₹0.6 Cr (+50.0% YoY) for Q1 FY27.
Choksi Laboratories has scheduled a Board Meeting for August 13, 2026, to consider unaudited financial results for the quarter ended June 30, 2026.
Choksi Laboratories Limited has changed its Registrar and Share Transfer Agent to Ankit Consultancy Private Limited, effective August 03, 2026. This is a routine administrative update.
Choksi Laboratories Limited filed its shareholding pattern as of 30 June 2026. The filing details promoter and various shareholder categories without monetary transaction.
Choksi Laboratories submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report notes minor past filing delays and current regulatory compliance.
Choksi Laboratories Ltd reported revenue from operations of ₹12.8 Cr (+12.3% YoY) and net profit of ₹1 Cr (+11.1% YoY) for Q4 FY26.
Choksi Laboratories reported annual revenue of ₹46.22 Crore for FY26. Net profit for the year reached ₹1.96 Crore, indicating stable operational performance for investors.
Choksi Laboratories appointed Mrs. Stela Choksi as CFO following Mr. Vyangesh Choksi's resignation. The transition occurred on May 18, 2026, ensuring leadership continuity.
Choksi Laboratories appointed Mrs. Stela Choksi as Chief Financial Officer. This leadership change strengthens executive management and supports regulatory compliance for the listed entity.
Mr. Vyangesh Choksi resigned as Chief Financial Officer of Choksi Laboratories, effective May 18, 2026. He remains the company's Whole Time Director.
Choksi Laboratories approved appointing Mrs. Stela Choksi as CFO following Mr. Vyangesh Choksi's resignation. The board also approved a car purchase and RTA change.
Choksi Laboratories scheduled a board meeting on May 25, 2026, to approve audited financial results for fiscal 2026. Trading window remains closed until 48 hours post-declaration.
Choksi Laboratories scheduled a board meeting for May 18, 2026, to discuss vehicle financing and RTA changes. Investors should monitor outcomes regarding CFO appointments.
Choksi Laboratories Ltd announced the results of its postal ballot conducted via remote e-voting. Shareholders approved the appointment of Mr. Ritik Pavecha as a Non-Executive Independent Director with a 99.86% majority. The voting period concluded on April 26, 2026, confirming the resolution's passage.
Choksi Laboratories Ltd disclosed it does not meet the 'Large Corporate' criteria for the fiscal year ended March 31, 2026. The company reported outstanding borrowings of ₹28.40 Crore. Consequently, the requirement for mandatory debt issuance under SEBI norms does not apply.
Choksi Laboratories Limited submitted a compliance certificate for the quarter ended March 31, 2026, as required under SEBI (Depositories and Participants) Regulations. The certificate from MUFG Intime India confirms that securities received for dematerialisation were processed and listed on the relevant exchanges within prescribed timelines.